IM
Immunovant
IMVT·NASDAQNew York NYFounded 2018200 employees
Mid CapbiotechPublicImmunologyNeurology
Platform: Batoclimab FcRn
Market Cap
$3B
All Drugs
3
Clinical Trials
6
Failed / Terminated
1
FDA Approved
1
Stock Price & Catalysts (IMVT)
Loading IMVT stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| IMV-2493 | IMV-2493 | Phase 2 | 1 | PSMA | SchizophreniaGBM | ||
| IMV-3202 | IMV-3202 | Approved | 4 | Tau | Parkinson'sPBC | ||
| IMV-3466 | IMV-3466 | Phase 1 | 1 | CD38 | FLSCLC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (6)